- Home
- OB vs DSGN Comparison
OB vs DSGN Comparison
Compare OB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- DSGN
- Stock Information
- Founded
- OB 2006
- DSGN 2017
- Country
- OB United States
- DSGN United States
- Employees
- OB N/A
- DSGN N/A
- Industry
- OB Industrial Machinery/Components
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- OB Industrials
- DSGN Health Care
- Exchange
- OB Nasdaq
- DSGN Nasdaq
- Market Cap
- OB 294.0M
- DSGN 224.8M
- IPO Year
- OB 2021
- DSGN 2021
- Fundamental
- Price
- OB $3.53
- DSGN $3.52
- Analyst Decision
- OB Buy
- DSGN Hold
- Analyst Count
- OB 6
- DSGN 1
- Target Price
- OB $6.58
- DSGN $4.00
- AVG Volume (30 Days)
- OB 348.6K
- DSGN 138.7K
- Earning Date
- OB 05-09-2025
- DSGN 05-07-2025
- Dividend Yield
- OB N/A
- DSGN N/A
- EPS Growth
- OB N/A
- DSGN N/A
- EPS
- OB N/A
- DSGN N/A
- Revenue
- OB $889,875,000.00
- DSGN N/A
- Revenue This Year
- OB $68.11
- DSGN N/A
- Revenue Next Year
- OB $6.22
- DSGN N/A
- P/E Ratio
- OB N/A
- DSGN N/A
- Revenue Growth
- OB N/A
- DSGN N/A
- 52 Week Low
- OB $3.00
- DSGN $2.60
- 52 Week High
- OB $7.87
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- OB 46.33
- DSGN 43.12
- Support Level
- OB $3.43
- DSGN $4.27
- Resistance Level
- OB $3.69
- DSGN $5.04
- Average True Range (ATR)
- OB 0.20
- DSGN 0.48
- MACD
- OB 0.03
- DSGN -0.03
- Stochastic Oscillator
- OB 51.90
- DSGN 16.16
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.